ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02000362
Recruitment Status : Unknown
Verified September 2016 by Kang Stem Biotech Co., Ltd..
Recruitment status was:  Recruiting
First Posted : December 4, 2013
Last Update Posted : September 6, 2017
Sponsor:
Information provided by (Responsible Party):
Kang Stem Biotech Co., Ltd.

Brief Summary:

The purpose of phase I clinical trial is to evaluate safety and efficacy in subjects with moderately active Crohn's disease after injection for 28days.

The purpose of phase IIa clinical trial is to determine therapeutic safety and efficacy of FURESTEM-CD Inj. which is based on Crohn's disease activity index(CDAI)<150 after injection.


Condition or disease Intervention/treatment Phase
Crohn's Disease Biological: Stem cells Phase 1 Phase 2

Detailed Description:

Crohn's disease is mysterious chronic inflammatory bowel disease. It usually happen in the young age and last forever. It is not yet clearly known the origin of crohn's disease. However, crohn's disease therapy is getting developed by using immunosuppressant and TNF-alpha inhibitor. Nonetheless, some patients still don't react to TNF-alpha inhibitor which is most effective treatment. Also, Even though some other patients reacted to the treatment at first, the effect of treatment decreases over time. Plus, long-term use of TNF-alpha inhibitor can lead to complication of infection and occurrence of malignant tumor like lymphoma. Recently, treatment of intractable crohn's disease is attempted by using stem cell. Especially, Mesenchymal stem cell is well-known for immunosuppression, anti-inflammatory ability and cell differentiation ability to various lineage cell as non hematopoietic stromal cell.

When the body get infected by the pathogens, innate immune response operate as the primary defence mechanism. at this time, there are some receptors reacting first such as TLR(toll-like receptor) and NLR(nucleotide-binding oligomerization domain) which is located in the cytoplasm of a cell. It is reported that the activities of TLR which is expressed by Mesenchymal stem cells play an important roles about immunomodulatory ability of Mesenchymal stem cells. Furthermore, human Umbilical Cord Blood derived-Universal Stem Cells( hUCB-USCs) manifest TLR and NLR of Mesenchymal Stem cells at the same time. when those receptors become activation, it maximize ability of immunomodulatory. Therefore, hUCB-USCs can be utilized to cure intractable autoimmune disease like Crohn's disease. Further, It has huge possibility as cell therapy products for autoimmune disease.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease
Study Start Date : August 2014
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : October 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Crohn's Disease

Arm Intervention/treatment
Experimental: Treatment

cohort 1. 5.0 x 10^7 stem cells after registration

cohort 2. 1.0 x 10^8 stem cells after registration

Biological: Stem cells
Other Name: FURESTEM-CD Inj.




Primary Outcome Measures :
  1. Number of Participants with Adverse Events, Ratio of patients who is applicable to CDAI<150 [ Time Frame: 4 weeks follow-up after treatment, 12 weeks follow-up after treatment ]
    on phase 1, Phase 2a


Secondary Outcome Measures :
  1. the ratio of patients who reduce CDAI over 70 as contrasted with baseline value [ Time Frame: 12 weeks follow-up after treatment ]
    on phase 2a

  2. a variation of CRP value as contrasted with baseline [ Time Frame: 12 weeks follow-up after treatment ]
    on phase 2a

  3. a variation of MR enterographic score as contrasted with baseline [ Time Frame: 12 weeks follow-up after treatment ]
    on phase 2a

  4. a variation of fecal calprotectin as contrasted with baseline [ Time Frame: 12 weeks follow-up after treatment ]
    on phase 2a

  5. a variation of IBDQ score as contrasted with baseline [ Time Frame: 12 weeks follow-up after treatment ]
    on phase 2a

  6. a variation of SF-36 score as contrasted with baseline [ Time Frame: 12 weeks follow-up after treatment ]
    on phase 2a

  7. reduction of the number of draining fistula [ Time Frame: 12 weeks follow-up after treatment ]
    on phase 2a

  8. all kinds of adverse effects which occur during the clinical study [ Time Frame: 12 weeks follow-up after treatment ]
    on phase 2a



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   19 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. of either gender, aged≥19 and ≤70 years
  2. subjects who is diagnosed with Crohn's disease after considering all the factors below.

    1. histological or pathological Diagnostic opinion
    2. colonoscopic Diagnostic opinion
    3. radiologic and hematological Diagnostic opinion
  3. subjects who is included in two criteria below and come under CDAI 220-450 during screening period.

    1. CRP>0.3mg/dL during screening period
    2. more than 3 nonanastomotic ulcers which is included in Crohn's disease as a result of colonoscopy on screening period(each diameter of ulcers needs to exceed 0.5cm)
  4. range of Crohn's disease : an affection of ileum, an affection of large intestine, an affection of ileum and large intestine at once.
  5. subjects who suffer from extensive colitis during more than 8 years or limited colitis during more than 12 years need to have evidence that there are no large intestine ulcers by surveillance colonoscopy on screening visit.
  6. subjects who are included in two criteria about drug treatment of Crohn's disease like below.

    1. subjects who fail the existing treatment and come under more than 1 criterion as below.

      • subjects who continuously administer Corticosteroid or immunosuppressant (AZA, Methotrexate, 6-MP)
      • subjects who have history of improper response or intolerance about Corticosteroid or immunosuppressant (AZA, Methotrexate, 6-MP)
      • subjects who are dependent Corticosteroid or have history of Corticosteroid dependence.
    2. subjects who have history of improper response or intolerance about anti-TNF treatment as below.

      • Infliximab
      • Adalimumab
      • Certolizumab pegol
  7. subjects who satisfy those clinical examination value below during screening period.

    • Hemoglobin ≥ 8.0g/dL
    • WBC ≥ 3,000/μL
    • Lymphocyte ≥ 500/μL
    • 100,000/μL ≤ Platelet ≤ 1,200,000/μL
    • AST and ALT ≤ 3 x the upper limit of normal
    • ALP ≤ 3 x the upper limit of normal
    • Serum creatinine ≤ the upper limit of normal
    • Serum albumin ≥ 2.0g/dL
    • PT ≤ the upper limit of normal
    • aPTT ≤ the upper limit of normal
  8. subjects who agree with those use of contraceptive method during clinical trial period.

    1. woman : subjects who is applicable to more than 1 case below.

      • subjects who is postmenopausal for more than 1 years before screening visit.
      • surgically sterility.
      • If subjects are biological clock, subjects need to agree with prohibition on having sex with man or usage of more than 2 effective contraception from sign of informed consent form until end of the clinical study.
    2. man : even surgically sterility(for example, getting a vasectomy), in case of satisfy those conditions below.

      • subjects who agree with prohibition on having sex with woman or usage of effective barrier contraception from sign of informed consent form until end of the clinical study.
  9. subjects who understand and voluntarily sign an informed consent form.

Exclusion Criteria:

  1. Exclusion Criteria of gastrointestinal tract

    1. Crohn's disease which is invaded only proximal ileum.
    2. the evidence of an intra-abdominal abscess during screening period.
    3. the evidence of an abscess around the anus during screening period.
    4. conditions of subtotal colectomy or total colectomy.
    5. short bowel syndrome.
    6. subjects who conduct elemental diet, tube feeding or parenteral nutrition within 3 weeks before registration.
    7. subjects who have ileostomy or colostomy.
    8. subjects who remove existing seton before screening period.
    9. fixed bowel stricture which has symptoms.
    10. In case that the PI anticipate that subjects need to get a surgical intestinal tract surgery caused by Crohn's disease.
    11. non-removal of large intestine adenoma.
    12. chronic inflammation-associated dysplasia.
  2. Exclusion Criteria of drugs

    1. in case subjects administered more than one drug within 4 weeks before enrollment.

      • Cyclosporine, tacrolimus, thalidomide
      • Adalimumab
      • Intravenous adrenocortical steroid
    2. in case subjects administered more than one drug within 10 weeks before enrollment.

      - Infliximab

      • Cetolizumab pegol
      • All kinds of biologicals
    3. in case subjects administered 5-ASA or Corticosteroid local treatment(a suppository or enema) within 2 weeks before enrollment.
    4. in case concomitant drug use for CD treatment cannot observe stable dosage during clinical study period or specified period like below.

      • use of oral 5-ASA compound at least 4 weeks before enrollment
      • use of oral Corticosteroid (prednisolone ≤ 20mg/day or budesonide ≤9mg/day) at least 2 weeks before enrollment
      • use of antibiotics for CD treatment at least 2 weeks before enrollment. (ex. metronidazole)
      • use of immunosuppressant at least 4 weeks before enrollment.
  3. Exclusion Criteria of infectious disease

    1. acute or chronic hepatitis like below(typeA, typeB, typeC).

      • IgM anti-HAV positive
      • HBs-Ag, IgM anti-HBc, IgG anti-HBc positive. (It is possible to enroll the clinical study when a subject is anti-HBs Ab positive, given that the subject is both HBs-Ag and IgM anti-HBc negative or IgG anti-HBc positive.)
      • HCV-Ab positive
    2. tuberculosis

      • status present active tuberculosis
      • latent tuberculosis : subjects who is applicable to more than 1 case below.

        • QuantiFERON TB-GOLD positive or 2times continuous indeterminate within 4weeks before registration.
        • more than 10mm in tuberculin skin test within 3 months before registration.(when subjects got injected prednisolone more than 15mg per day, limited tuberculin skin test value is 5mm)
        • In case of observation of pulmonary tuberculosis cicatrix through X-Ray within 3months before registration.
    3. All kinds of Congenital or Acquired Immunodeficiency Syndrome.
    4. all kinds of live vaccine inoculation except influenza vaccine within 4weeks before registration.
    5. Clinically Significant infection with in 4weeks before screening visit or during screening visit.(pneumonia, pyelonephritis, Infection of Clostridium difficile etc.)
  4. General exclusion Criteria a. subjects who experienced stem cell therapy. b. History of a malignant tumor except as noted below.

    • properly cured non-metastatic basal cell skin cancer
    • properly cured pinacocyte skin cancer which is not recurred at least 1 year before registration.
    • properly cured carcinoma in situ of uterine cervix which has not recurred at least 3 years before registration.

      c. malignant tumor which is not cured yet. d. subjects who are breast-feeding. e. unstable and not regulated disease(associated with cardiovascular, lung, liver, kidney, gastrointestinal tract, urogenital organs, hematologic, immune, endocrine/metabolism, etc.) which has possibility to hamper safety of subjects or cause confusion in clinical study.

      f. subjects who got general anesthesia surgery within 4weeks before registration or subjects who anticipated necessity of general anesthesia surgery during clinical study.

      g. major neurological history including stroke, multiple sclerosis, encephaloma, neurological degenerative disease.

      h. history of hypersensitive reaction about MR contrast medium. I. history of addictive drugs or alcohol with 1 years. j. active psychiatric problem which can hamper participation of clinical study. k. all kinds of problems which has possibility to hamper participation of study visit and observance of study procedure.

      l. Any other condition which the PI judges would make subject unsuitable for study participation.

      m. subjects who got injected other investigational product within 4 weeks or at present.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02000362


Contacts
Contact: Eun-ji Kang ejkang@kangstem.com

Locations
Korea, Republic of
Inje University Haeundae Paik Hospital Recruiting
Busan, Korea, Republic of, 48108
Contact: Tae-oh Kim         
Yeungnam University Medical Center Recruiting
Daegu, Korea, Republic of, 42415
Contact: Byung-Ik Jang         
Seoul National Universtiy Bundang Hospital Recruiting
Seongnam-si, Korea, Republic of, 13620
Contact: Hyuk Yoon         
Principal Investigator: Hyuk Yoon         
Severance Hospital Recruiting
Seoul, Korea, Republic of, 03722
Contact: Jae-hee Cheon         
Asan Medical Center Recruiting
Seoul, Korea, Republic of, 138-736
Contact: Su-jung Kim         
Contact: Ji-young Park         
Principal Investigator: Suk-kyun Yang         
Soeul National University Hospital Recruiting
Soeul, Korea, Republic of, 110-7441
Contact: Jong-pil Im         
Principal Investigator: Jong-pil Im         
The Catholic University of Korea, St. Vincent`S Hospital. Recruiting
Suwon-si, Korea, Republic of, 16247
Contact: Kang-moon Lee         
Sponsors and Collaborators
Kang Stem Biotech Co., Ltd.
Investigators
Principal Investigator: Suk-kyun Yang Asan Medical Center

Responsible Party: Kang Stem Biotech Co., Ltd.
ClinicalTrials.gov Identifier: NCT02000362     History of Changes
Other Study ID Numbers: KSTHD_FURESTEM-CD
First Posted: December 4, 2013    Key Record Dates
Last Update Posted: September 6, 2017
Last Verified: September 2016

Keywords provided by Kang Stem Biotech Co., Ltd.:
Crohn's Disease
Stem cell
Cell therapy
Auto-immune disease
furestem
CD
inflammatory bowel disease
MSCs
Mesenchymal Stem Cells
hUCB-MSC
UCB-MSC
Umbilical cord Blood

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases